ERBB2 and cancer: Hence, mutp53 status in ErbB2 positive cancer cells predicts higher sensitivity to lapatinib via two complementary mechanisms: mutp53-mediated amplification of ErbB2, and simultaneous targeting of potent oncogenic drivers, ErbB2, mutp53 and HSF1 by ErbB2 inhibition.